Search Results
Your search for ,sIX matches 2928 pages
Showing 1151 - 1200High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
Personalized Medicine Meets Geriatric Oncology: Tailoring Oncologic Care for Older Adults
The ASCO20 Virtual Scientific Program was a landmark year for the field of geriatric oncology, featuring more than 300 research abstracts that presented data on older adults with cancer. Here, we discuss several high-impact studies investigating interventions that modify outcomes for this patient...
Messino Cancer Centers Founder Michael Messino, MD, Receives North Carolina Governor’s Award
Messino Cancer Centers, a partner practice of American Oncology Network, announced that medical oncologist Michael Messino, MD, has received the highest award granted by North Carolina’s Office of the Governor. The Order of the Long Leaf Pine is presented to individuals who have shown extraordinary ...
Lymphomas in Adolescents and Young Adults Deserve Further Study
Adolescents and young adults (AYAs) with lymphoma are a unique population, with distinct biology, disparities in outcome, poorer survival compared with children and adults, and variable impacts of treatments. Ongoing research on this patient population with lymphoma will hopefully lead to improved...
Fine-Tuning CAR T-Cell Therapy for Lymphomas
Chimeric antigen receptor (CAR) T-cell therapies are a major advance in the treatment of hematologic malignancies and are making inroads in solid tumors, but there is room for improvement in their design, since not all patients respond, and those who do may relapse. Researchers are studying...
New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials
A new study published by Kichenadasse et al in JNCCN—Journal of the National Comprehensive Cancer Network concentrates on how immunotherapy-related adverse events may impact more than one organ in a single patient. This study provides new information on how frequently multiorgan side effects occur...
CLL14 Trial Follow-up: Venetoclax Plus Obinutuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
As reported in The Lancet Oncology by Al-Sawaf et al, 3-year follow-up of the phase III CLL14 trial showed maintained significant improvement in progression-free survival with the fixed-duration regimen of venetoclax/obinutuzumab vs chlorambucil/obinutuzumab in previously untreated patients with...
Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma
Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Amanda N. Fader, MD, of Johns Hopkins School of Medicine, Baltimore, and colleagues in Clinical...
SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
KEYNOTE-100: In Women With Advanced Ovarian Cancer, Pembrolizumab Yields Modest Antitumor Efficacy
the final results of the phase II KEYNOTE-100 study of pembrolizumab in women with advanced and recurrent ovarian cancer showed that pembrolizumab monotherapy produced modest clinical activity. Ursula Matulonis, MD, of Dana-Farber Cancer Institute, Harvard Medical School, reported the data at the...
ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Ovarian Cancer
In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 20191 and simultaneously published in The New England Journal of Medicine2—Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the ...
Does Binimetinib Improve Progression-Free Survival in Recurrent or Persistent Low-Grade Serous Ovarian Carcinomas?
As reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ARRAY-162-311/ENGOT-ov11 trial showed that the MEK1/2 inhibitor binimetinib did not improve progression-free survival vs physician’s choice...
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 Trial
As reported in The Lancet Oncology by Véronique Diéras, MD, and colleagues, the phase III BROCADE3 trial showed a significant improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin and paclitaxel in patients with...
Comparing Pazopanib to Doxorubicin in Patients Aged 60 and Older With Soft-Tissue Sarcoma
Doxorubicin is a standard of care in patients with advanced inoperable soft-tissue sarcoma. In the EPAZ study, German researchers tested whether pazopanib showed comparable efficacy to doxorubicin in the first-line treatment of elderly patients with soft-tissue sarcoma. Grünwald et al reported in...
Changes in Reoperation Rates After Publication of SSO/ASTRO Guideline on Margins for Breast-Conserving Surgery
In a meta-analysis reported in JAMA Surgery, Marinovich et al found that reoperation rates after breast-conserving surgery in women with breast cancer declined after the publication of the Society of Surgical Oncology/American Society for Radiation Oncology (SSO/ASTRO) Consensus Guideline on...
Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?
After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...
Addition of Nelarabine to Standard Therapy in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
As reported in the Journal of Clinical Oncology by Dunsmore et al, the phase III Children’s Oncology Group AALL0434 trial has shown that the addition of nelarabine to standard therapy improved disease-free survival in children and young adults with newly diagnosed T-cell acute lymphoblastic...
One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy
Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cambodia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cambodia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Mary-Claire King, PhD, Honored With 2020 William L. McGuire Memorial Lecture Award
Mary-Claire King, PhD, will receive the William L. McGuire Memorial Lecture Award at the 2020 San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8 to 12, 2020. The William L. McGuire Memorial Lectureship was established in 1992 to commemorate Dr. McGuire’s significant...
Rural Cancer Care: Models of Success and Barriers Highlighted in New State of Cancer Care in America Package
JCO Oncology Practice has published an article on rural cancer care as part of the State of Cancer Care in America series. “Closing the Rural Cancer Care Gap: Three Institutional Approaches” draws from data presented during the second State of Cancer Care in America live event as well as supporting ...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...
Heather Brandt, PhD, to Lead Cancer Prevention Community Outreach Projects for St. Jude
St. Jude Children’s Research Hospital has appointed Heather Brandt, PhD, a behavioral scientist with expertise in cancer prevention and control, to lead community outreach and research programs focused on the prevention of human papillomavirus (HPV)-associated cancers through vaccination. In...
Activity of Olaparib and Durvalumab in Germline BRCA-Mutated Metastatic Breast Cancer
As reported in The Lancet Oncology by Susan M. Domchek, MD, and colleagues, the combination of olaparib and durvalumab showed activity in a cohort of patients with germline BRCA-mutated, HER2-negative metastatic breast cancer enrolled in a phase I/II basket study (MEDIOLA). Study Details In the...
Early Rituximab Intensification in R-CHOP for Diffuse Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Pieternella Johanna Lugtenburg, MD, PhD, and colleagues, the phase III Haemato-Oncology Foundation for Adults in the Netherlands (HOVEN)/ Nordic Lymphoma Group HOVON-84 trial showed that early rituximab intensification in R-CHOP-14 (rituximab plus...
Study Finds Residents of Low-Income Neighborhoods Have Less Access to ICU Beds Amidst Coronavirus Pandemic
A new study published by Kanter et al in Health Affairs sheds light on another reason why the coronavirus pandemic is disproportionately affecting individuals of lower socioeconomic status: residents in low-income neighborhoods lack access to intensive care unit (ICU) beds. While the shortage of...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented during the ASCO20 Virtual Scientific Program by Elizabeth R....
Maintenance Avelumab Improves Survival in Advanced Bladder Cancer
Maintenance therapy with avelumab and best supportive care significantly prolonged overall survival vs best supportive care alone in patients with advanced urothelial carcinoma that did not progress on first-line platinum-based chemotherapy, according to an interim analysis of the phase III JAVELIN ...
Salvage Nivolumab Plus Ipilimumab After Prior Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Renal Cell Carcinoma
In a study reported in the Journal of Clinical Oncology,1 Anita Gul, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues found that salvage therapy with nivolumab/ipilimumab was capable of producing a response after prior PD-1 pathway inhibitor therapy in some patients with...
Enzalutamide Improves Survival vs Standard First-LineTreatment in Hormone-Sensitive Metastatic Prostate Cancer
As reported inThe New England Journal of Medicine by Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of Monash University and Eastern Health in Melbourne, and colleagues, the phase III ENZAMET trial has shown that the androgen receptor inhibitor enzalutamide improved progression-free and overall survival...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented during the ASCO20 Virtual Scientific Program1 and published as a brief report in JAMA Oncology,2 Praful Ravi, MB, BChir, of the Dana-Farber Cancer Institute, Boston, and colleagues found that rechallenge with immune checkpoint inhibitor therapy was capable of producing...
Pembrolizumab Monotherapy as First-Line Treatment for Patients With Unresectable Cutaneous Squamous Cell Carcinoma
In the French phase II CARSKIN trial reported in the Journal of Clinical Oncology, Maubec et al found that pembrolizumab monotherapy produced durable responses in the first-line treatment of unresectable cutaneous squamous cell carcinoma. Study Details In the multicenter trial, 39 patients (primary ...
Fixed-Dose Subcutaneous Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf in HER2-Positive Breast Cancer
On June 29, 2020, a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) for subcutaneous injection was approved for the following indications1,2: Use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced,...
Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient
Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...
Lost in Translation: A Fisherman’s Tale
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
National Comprehensive Cancer Network Celebrates Its 25th Year
It was February 1996, and the first annual meeting of the National Comprehensive Cancer Network® (NCCN®) was drawing to a close, when Chief Executive Officer (CEO) Bruce R. Ross, MD, invited comments from the floor. An oncologist who had attended at the urging of a friend—somewhat reluctantly—stood ...
Multiple Lesions Not a Contraindication for Cosmetically Acceptable Lumpectomy
More than 70% of women with multiple tumors in a single breast reported good or excellent satisfaction with the cosmetic results of breast-conserving therapy, Alliance (ACOSOG) Z11102 investigators reported at the 2020 American Society of Breast Surgeons (ASBrS) Virtual Scientific Session.1 In...
First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...
Overcoming the Challenges of Improving Psychosocial Care for Patients With Cancer
Although the United States spends billions of dollars each year on cancer research, very little of that funding is dedicated to mental health research in patients with cancer, despite the fact that cancer survivors have a six-time higher risk for psychological disability than people without...
Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial has shown that treatment with pembrolizumab resulted in durable responses in patients with recurrent or metastatic cutaneous squamous cell carcinoma. The study supported the...
Outcomes With PET-Directed Therapy for Limited-Stage DLBCL
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in patients with limited-stage diffuse large B-cell lymphoma ...
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
According to research published by Russell et al in Frontiers in Oncology, patients with a longer-established diagnosis of cancer are at increased risk for more severe infection with COVID-19, as well as death from the virus. Patients of Asian ethnicity or who were receiving palliative treatment...
Weathering the Storm: Personal Steps Toward Racial Equity in Oncology
“Of all the forms of inequality, injustice in health is the most shocking and the most inhumane because it often results in physical death. I see no alternative to direct action and creative nonviolence to raise the conscience of the nation.” —Martin Luther King, Jr, speaking before the Medical...
The Wake
The ASCO Post is pleased to reproduce installments of the “Art of Oncology,” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
Addition of Rituximab to Standard Chemotherapy Improves Event-Free and Overall Survival in Children With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Véronique Minard‑Colin, MD, PhD, of Gustave Roussy, Université Paris-Saclay, Villejuif, France, and colleagues found that the addition of rituximab...
When Paired With Palbociclib, Fulvestrant and Letrozole Yield Comparable Results in PARSIFAL Trial
When paired with palbociclib in the first-line treatment of metastatic breast cancer, fulvestrant and letrozole performed comparably, with no statistical superiority in progression-free or overall survival shown for either endocrine agent, in the phase II PARSIFAL study presented during the ASCO20...
Effect of Breast Cancer Pathway Implementation on Rate of Referrals for Genetic Counseling and Testing
In a study reported in JCO Oncology Practice, Stephanie L. Graff, MD, and colleagues found that patients with breast cancer seen by a physician with training in using an established pathway for genetic counseling and testing referral were more frequently referred for such services vs patients seen...
